Forbes J M & Co. LLP Reduces Stock Position in Becton, Dickinson and Company (NYSE:BDX)

Forbes J M & Co. LLP lowered its position in shares of Becton, Dickinson and Company (NYSE:BDXFree Report) by 3.7% in the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 34,849 shares of the medical instruments supplier’s stock after selling 1,356 shares during the period. Forbes J M & Co. LLP’s holdings in Becton, Dickinson and Company were worth $8,623,000 at the end of the most recent reporting period.

Several other institutional investors have also added to or reduced their stakes in the company. Aua Capital Management LLC purchased a new stake in shares of Becton, Dickinson and Company in the 1st quarter worth about $202,000. &PARTNERS purchased a new stake in shares of Becton, Dickinson and Company in the 1st quarter worth about $711,000. Running Oak Capital LLC lifted its position in shares of Becton, Dickinson and Company by 16.2% in the 1st quarter. Running Oak Capital LLC now owns 37,502 shares of the medical instruments supplier’s stock worth $9,280,000 after purchasing an additional 5,227 shares during the period. Gulf International Bank UK Ltd lifted its position in shares of Becton, Dickinson and Company by 0.6% in the 1st quarter. Gulf International Bank UK Ltd now owns 25,075 shares of the medical instruments supplier’s stock worth $6,204,000 after purchasing an additional 159 shares during the period. Finally, Financiere des Professionnels Fonds d investissement inc. lifted its position in shares of Becton, Dickinson and Company by 18.5% in the 1st quarter. Financiere des Professionnels Fonds d investissement inc. now owns 54,913 shares of the medical instruments supplier’s stock worth $13,588,000 after purchasing an additional 8,586 shares during the period. Hedge funds and other institutional investors own 86.97% of the company’s stock.

Becton, Dickinson and Company Stock Performance

Shares of BDX stock traded down $0.11 during trading hours on Friday, reaching $238.29. The company had a trading volume of 2,014,700 shares, compared to its average volume of 1,476,021. The business has a fifty day moving average price of $234.35 and a 200-day moving average price of $237.87. Becton, Dickinson and Company has a one year low of $224.00 and a one year high of $287.32. The firm has a market cap of $68.87 billion, a PE ratio of 52.49, a price-to-earnings-growth ratio of 2.09 and a beta of 0.44. The company has a debt-to-equity ratio of 0.62, a quick ratio of 0.97 and a current ratio of 1.41.

Becton, Dickinson and Company (NYSE:BDXGet Free Report) last announced its quarterly earnings results on Thursday, May 2nd. The medical instruments supplier reported $3.17 EPS for the quarter, topping analysts’ consensus estimates of $2.97 by $0.20. Becton, Dickinson and Company had a net margin of 6.76% and a return on equity of 13.90%. The firm had revenue of $5.05 billion during the quarter, compared to analyst estimates of $5.04 billion. During the same period in the previous year, the business posted $2.86 earnings per share. The business’s revenue for the quarter was up 4.6% on a year-over-year basis. Sell-side analysts predict that Becton, Dickinson and Company will post 13.04 earnings per share for the current fiscal year.

Becton, Dickinson and Company Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, June 28th. Investors of record on Monday, June 10th will be issued a $0.95 dividend. This represents a $3.80 dividend on an annualized basis and a dividend yield of 1.59%. The ex-dividend date of this dividend is Monday, June 10th. Becton, Dickinson and Company’s payout ratio is 83.70%.

Insider Buying and Selling

In related news, SVP Thomas J. Spoerel sold 300 shares of the firm’s stock in a transaction that occurred on Monday, June 10th. The shares were sold at an average price of $239.31, for a total value of $71,793.00. Following the transaction, the senior vice president now owns 1,976 shares of the company’s stock, valued at $472,876.56. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. In other Becton, Dickinson and Company news, EVP Roland Goette sold 3,300 shares of Becton, Dickinson and Company stock in a transaction that occurred on Monday, May 13th. The shares were sold at an average price of $236.70, for a total transaction of $781,110.00. Following the transaction, the executive vice president now owns 14,608 shares of the company’s stock, valued at $3,457,713.60. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, SVP Thomas J. Spoerel sold 300 shares of Becton, Dickinson and Company stock in a transaction that occurred on Monday, June 10th. The shares were sold at an average price of $239.31, for a total transaction of $71,793.00. Following the transaction, the senior vice president now directly owns 1,976 shares in the company, valued at approximately $472,876.56. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 8,615 shares of company stock valued at $2,033,381. 0.31% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently commented on the stock. The Goldman Sachs Group assumed coverage on shares of Becton, Dickinson and Company in a research report on Thursday, May 30th. They issued a “buy” rating and a $274.00 target price for the company. StockNews.com lowered shares of Becton, Dickinson and Company from a “buy” rating to a “hold” rating in a research note on Friday, June 14th. Finally, Barclays increased their price target on shares of Becton, Dickinson and Company from $305.00 to $312.00 and gave the stock an “overweight” rating in a research note on Monday, May 6th. Two research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $280.17.

Read Our Latest Analysis on BDX

Becton, Dickinson and Company Company Profile

(Free Report)

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.

Read More

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton, Dickinson and Company (NYSE:BDXFree Report).

Institutional Ownership by Quarter for Becton, Dickinson and Company (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Company and related companies with MarketBeat.com's FREE daily email newsletter.